Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
MWN-AI** Summary
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a leading biopharmaceutical company focused on developing innovative cancer therapies, announced its participation in the upcoming Guggenheim Emerging Outlook: Biotech Summit set for February 11-12, 2026. The company’s management will engage in a fireside chat at 9:30 AM EST on February 12, allowing investors and analysts to gain insights into Ascentage’s strategic direction and pipeline advancements. Interested parties can access the webcast on the company’s Investor Relations webpage.
Ascentage is notable for its focus on addressing unmet medical needs in oncology through a robust portfolio of drug candidates. Among its lead products, Olverembatinib stands out as the first third-generation BCR-ABL1 inhibitor approved in China for treating chronic myeloid leukemia (CML) variants with T315I mutations, among other indications. Supported by the China National Reimbursement Drug List, the drug is currently involved in a global Phase III trial, POLARIS-2, to improve treatment outcomes for CML patients.
Additionally, the company’s Bcl-2 inhibitor, Lisaftoclax, has secured approval for various hematologic malignancies in China, with ongoing global Phase III studies addressing CLL/SLL and other blood disorders. By leveraging its advanced R&D capabilities, Ascentage has established significant collaborations with top-tier pharmaceutical companies and research institutions.
As the biotech sector continues to evolve, Ascentage Pharma’s participation in major industry gatherings like the Guggenheim Summit underscores its commitment to innovation and its potential to make significant contributions to cancer treatment. This strategic engagement offers stakeholders an opportunity to better understand the company’s vision amidst a complex biopharmaceutical landscape.
MWN-AI** Analysis
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) is a noteworthy player in the biopharmaceutical sector, particularly concerning its innovative cancer therapies. With its participation in the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026, the company is poised to attract investor interest and potentially bolster its market visibility.
Investors should consider several factors before making decisions regarding Ascentage Pharma. Firstly, the company’s pipeline shows promising potential, showcasing innovative treatments such as Olverembatinib, a third-generation BCR-ABL1 inhibitor, and Lisaftoclax, a novel Bcl-2 inhibitor. Both have earned approvals in China and are currently undergoing global registrational Phase III trials, which could lead to significant revenue streams if successful.
The global partnerships Ascentage has forged with major pharmaceutical companies like Takeda, AstraZeneca, and Pfizer enhance its research and development capabilities, providing additional confidence in its future product offerings. Such collaborations can also accelerate clinical development timelines and enhance market reach, making the firm a compelling option for investors seeking growth in the biotechnology sector.
However, investors must also remain cautious of the inherent risks associated with biopharmaceutical companies, which often involve lengthy regulatory processes and high clinical trial costs. As mentioned in the company’s forward-looking statements, there are uncertainties that could lead to variability in performance.
In summary, Ascentage Pharma presents a promising investment opportunity, given its innovative therapies and strong pipeline. However, potential investors should conduct thorough due diligence, considering both the opportunities and risks outlined in their SEC filings, to determine if this stock aligns with their investment strategy. With the biopharmaceutical market continuing to grow, Ascentage may be an attractive option for those looking to diversify into this sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ROCKVILLE, Md. and SUZHOU, China, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company, a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 being held on February 11-12, 2026.
The management team will be participating in a fireside chat at 9:30 am EST on Thursday, February 12th. The webcast can be accessed by visiting the Events page in the Investor Relations section of Ascentage’s website.
About Ascentage Pharma
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, as well as next-generation kinase inhibitors.
The lead asset, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of Olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.
The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax is being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including BTK inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia (AML); and the GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS), a study that was simultaneously cleared by the U.S. FDA, the EMA of the EU, and China CDE.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.
These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Special note regarding forward-looking statements and industry data” in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investor Relations:
Yuly Chen, Senior Investor Relations Director
Ascentage Pharma
IR@ascentage.com
+86 512 85557777
+1 (301) 792-5658
Stephanie Carrington
ICR Healthcare
AscentageIR@icrhealthcare.com
+1 (646) 277-1282
Media Relations:
Sean Leous
ICR Healthcare
AscentagePR@icrhealthcare.com
+1 (646) 866-4012
FAQ**
How does Ascentage Pharma Group International (AAPG) plan to leverage its partnerships in both Rockville, Md., and Suzhou, China, to enhance its drug development pipeline?
In what ways does Ascentage Pharma Group International (AAPG) anticipate the outcomes of its Phase III trials will impact its market positioning in Rockville, Md., and Suzhou, China?
What specific unmet medical needs in cancer does Ascentage Pharma Group International (AAPG) aim to address with its therapies in both Rockville, Md., and Suzhou, China?
How does Ascentage Pharma Group International (AAPG) plan to navigate regulatory and market challenges in the biopharmaceutical sectors of Rockville, Md., and Suzhou, China?
**MWN-AI FAQ is based on asking OpenAI questions about Ascentage Pharma Group (OTC: ASPHF).
NASDAQ: ASPHF
ASPHF Trading
178.06% G/L:
$8.48 Last:
100 Volume:
$8.48 Open:
